Name
Title | ||
|---|---|---|
In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: A case study on the cancer MAPK signaling pathway. |
Abstract | ||
|---|---|---|
•A noncognate interaction profile between MAPK kinases and approved inhibitors is created.•An integration of in silico analysis and in vitro assay is used to characterize the profile.•A number of putative MAPK–inhibitor pairs are identified.•The Regorafenib is suggested as a potential noncognate inhibitor of p38α kinase. |
Year | DOI | Venue |
|---|---|---|
2018 | 10.1016/j.compbiolchem.2018.05.012 | Computational Biology and Chemistry |
Keywords | Field | DocType |
Mitogen-activated protein kinase,Kinase inhibitor,Untargeted interaction,Biomolecular modeling,Cancer | Cabozantinib,Crizotinib,Biology,Kinase,Cancer research,Regorafenib,MAPK/ERK pathway,Signal transduction,Bioinformatics,Protein kinase domain,Protein kinase A | Journal |
Volume | ISSN | Citations |
75 | 1476-9271 | 0 |
PageRank | References | Authors |
0.34 | 10 | 2 |
Name | Order | Citations | PageRank |
|---|---|---|---|
| Li Meng | 1 | 2 | 2.08 |
| Zhijun Huang | 2 | 0 | 0.34 |